CN1738833A - Hcv疫苗 - Google Patents

Hcv疫苗 Download PDF

Info

Publication number
CN1738833A
CN1738833A CNA200380108865XA CN200380108865A CN1738833A CN 1738833 A CN1738833 A CN 1738833A CN A200380108865X A CNA200380108865X A CN A200380108865XA CN 200380108865 A CN200380108865 A CN 200380108865A CN 1738833 A CN1738833 A CN 1738833A
Authority
CN
China
Prior art keywords
hcv
core
polynucleotide
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200380108865XA
Other languages
English (en)
Chinese (zh)
Inventor
S·布雷特
P·A·汉布林
L·奥吉尔维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1738833A publication Critical patent/CN1738833A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA200380108865XA 2002-11-15 2003-11-13 Hcv疫苗 Pending CN1738833A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226722.7 2002-11-15
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
CN1738833A true CN1738833A (zh) 2006-02-22

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200380108865XA Pending CN1738833A (zh) 2002-11-15 2003-11-13 Hcv疫苗
CNA2003801088698A Pending CN1738834A (zh) 2002-11-15 2003-11-13 Hcv 疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2003801088698A Pending CN1738834A (zh) 2002-11-15 2003-11-13 Hcv 疫苗

Country Status (21)

Country Link
US (4) US20060135451A1 (2)
EP (2) EP1560845A1 (2)
JP (2) JP2006518331A (2)
KR (2) KR20050085010A (2)
CN (2) CN1738833A (2)
AR (1) AR041964A1 (2)
AU (2) AU2003288084A1 (2)
BR (2) BR0316244A (2)
CA (2) CA2504654A1 (2)
CO (1) CO5700833A2 (2)
GB (1) GB0226722D0 (2)
IS (2) IS7831A (2)
MA (2) MA27700A1 (2)
MX (2) MXPA05005202A (2)
NO (2) NO20052136L (2)
NZ (2) NZ539998A (2)
PL (2) PL376882A1 (2)
RU (2) RU2363492C2 (2)
TW (1) TW200502246A (2)
WO (2) WO2004046176A1 (2)
ZA (2) ZA200503802B (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8178086B2 (en) * 2006-01-04 2012-05-15 Novartis Vaccines And Diagnostics, Inc. Activation of HCV specific T cells
MX2008011361A (es) * 2006-03-09 2008-09-15 Transgene Sa Proteina de fusion no-estructural del virus de hepatitis c.
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
WO2010011870A2 (en) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions and methods for the treatment of hepatitis c
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
JP2016513115A (ja) * 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
HUT77870A (hu) * 1994-10-05 1998-09-28 Apollon, Inc. Hepatitiszvírus elleni vakcinák
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CA2379235A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services, Centers For Disease Co Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
NZ539998A (en) 2008-04-30
BR0316244A (pt) 2005-10-04
RU2363492C2 (ru) 2009-08-10
GB0226722D0 (en) 2002-12-24
CO5700833A2 (es) 2006-11-30
ZA200503803B (en) 2006-08-30
MXPA05005202A (es) 2006-01-27
CA2504715A1 (en) 2004-06-03
WO2004046176A1 (en) 2004-06-03
KR20050085010A (ko) 2005-08-29
AR041964A1 (es) 2005-06-01
US20090232847A1 (en) 2009-09-17
JP2006518331A (ja) 2006-08-10
US20090104231A1 (en) 2009-04-23
NO20052149D0 (no) 2005-05-02
MA27700A1 (fr) 2006-01-02
BR0316291A (pt) 2005-10-11
ZA200503802B (en) 2006-08-30
AU2003288084A1 (en) 2004-06-15
IS7831A (is) 2005-04-28
PL376882A1 (pl) 2006-01-09
NZ539999A (en) 2008-03-28
KR20050085009A (ko) 2005-08-29
EP1560845A1 (en) 2005-08-10
US20060246090A1 (en) 2006-11-02
NO20052136D0 (no) 2005-05-02
AU2003288072A1 (en) 2004-06-15
TW200502246A (en) 2005-01-16
RU2323744C2 (ru) 2008-05-10
IS7830A (is) 2005-04-28
CA2504654A1 (en) 2004-06-03
NO20052136L (no) 2005-07-11
JP2006524181A (ja) 2006-10-26
NO20052149L (no) 2005-07-11
EP1560844A1 (en) 2005-08-10
MA27699A1 (fr) 2006-01-02
CN1738834A (zh) 2006-02-22
MXPA05005203A (es) 2006-01-27
PL376967A1 (pl) 2006-01-23
WO2004046175A1 (en) 2004-06-03
US20060135451A1 (en) 2006-06-22
RU2005113692A (ru) 2006-01-27
RU2005113691A (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
CN1738833A (zh) Hcv疫苗
CN1229501C (zh) Hiv多包膜蛋白疫苗的重组痘苗载体混合物
CN1606624A (zh) 疫苗
CN1791678A (zh) 改进的甲病毒复制子和辅助构建体
CN1756845A (zh) 腺病毒载体疫苗
CN1636015A (zh) Hcv e1e2疫苗组合物
CN1833022A (zh) 包含HCV的多蛋白NS3/NS4和多肽NS5b的组合物,包括相应核酸序列的表达载体及它们的治疗应用
CN1950106A (zh) 用作肿瘤特异性疫苗的合成蛋白质
CN1452634A (zh) Hla结合肽及其用途
CN1281748C (zh) 为改善IL－12活性而突变的IL－12p40亚基基因及其作为DNA疫苗佐剂的用途
CN1678630A (zh) 具有修饰的ns3结构域的hcv融合蛋白
JP4647870B2 (ja) Ｈｂｖ／ｈｃｖウイルス様粒子
CN100335637C (zh) 采用丙型肝炎病毒非结构蛋白进行的基因免疫
CN1249241C (zh) Hiv样颗粒及其用途
CN1566342A (zh) Sars冠状病毒的s蛋白的抗原表位、其抗体、编码核酸以及含有它们的组合物
CN1701120A (zh) 用于基因表达的核酸构建体
CN1717416A (zh) 丙型肝炎病毒非结构蛋白4a(ns4a)是增强子元件
CN1289146C (zh) 一种新型预防和治疗乙肝病毒感染的核酸疫苗及制备方法
CN1462636A (zh) 预防和治疗人丙型肝炎病毒感染的重组蛋白疫苗及其用途
CN1234851C (zh) 抗人乳头状瘤病毒疫苗
CN1594359A (zh) 乙型肝炎疫苗及其制备方法
CN1524952A (zh) 一种以登革热病毒重组复制子为载体的假病毒颗粒疫苗
HK1084147A (en) Hcv fusion proteins with modified ns3 domains
HK1071377A (en) Flavivirus ns1 subunit vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060222